Evotec SE (ETR:EVT)
Germany
· Delayed Price · Currency is EUR 7.14
-0.06 (-0.81%)
Jun 27, 2025, 5:35 PM CET
Evotec SE Revenue
Evotec SE had revenue of 199.98M EUR in the quarter ending March 31, 2025, a decrease of -4.19%. This brings the company's revenue in the last twelve months to 788.22M, up 1.50% year-over-year. In the year 2024, Evotec SE had annual revenue of 796.97M with 1.99% growth.
Revenue (ttm)
788.22M
Revenue Growth
+1.50%
P/S Ratio
1.61
Revenue / Employee
165.38K
Employees
4,740
Market Cap
1.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 796.97M | 15.54M | 1.99% |
| Dec 31, 2023 | 781.43M | 29.98M | 3.99% |
| Dec 31, 2022 | 751.45M | 133.41M | 21.59% |
| Dec 31, 2021 | 618.03M | 117.11M | 23.38% |
| Dec 31, 2020 | 500.92M | 54.49M | 12.20% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Siemens Healthineers AG | 23.14B |
| Merck KGaA | 21.32B |
| Bayer Aktiengesellschaft | 46.58B |
| Fresenius SE & Co. KGaA | 22.13B |
| Fresenius Medical Care AG | 19.49B |
| Sartorius Aktiengesellschaft | 3.44B |
| Carl Zeiss Meditec AG | 2.17B |
| Fielmann Group AG | 2.33B |
Evotec SE News
- 2 days ago - Evotec's Collaboration Sparks Hope For Acute Kidney Injury Breakthroughs - Benzinga
- 3 days ago - Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury - Wallstreet:Online
- 3 days ago - Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury - Accesswire
- 8 days ago - EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 24 days ago - Evotec SE Unveils Key Outcomes from 2025 AGM - Wallstreet:Online
- 24 days ago - EQS-News: Evotec SE: Results of the Annual General Meeting 2025 - Wallstreet:Online
- 7 weeks ago - Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments - Wallstreet:Online
- 7 weeks ago - Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments - Accesswire